Executive leader in health policy, pharmaceutical & medical device policy, and real-world evidence (RWE) development with leadership experience in the CRO/payer, academic, DC-based think-tank and life sciences corporate environments. Dedicated to advancing policies that support high-value innovation that meets patient unmet needs and policies that enable equitable and affordable access. Editor-in-Chief, Therapeutic Innovation and Regulatory Science (TIRS) peer-reviewed scientific journal; member of Board of Directors, Innovation in Value Initiative (IVI).Policy expertise: ♦ Drug and medical device payment and coverage policy♦ Value-based healthcare reforms♦ Regulatory science, drug/device development policy♦ Improving the use of real-world evidence (RWE) to support regulatory and payer decisions.Data and research expertise:♦ RWE, health economics and outcomes research, comparative effectiveness research, and drug safety and pharmacoepidemiology ♦ Biostatistics and epidemiology♦ Leveraging real world data from health insurance claims and EHRs to support research that addresses questions about value in healthcare.